Skip to main content
SpringerLink
Log in

Neue BRAF-/MEK-Hemmer-Kombination für Melanomtherapie

  • Dermatoonkologie
  • Literatur kompakt
  • Published:
Im Focus Onkologie Aims and scope

Die Kombination aus BRAF- und MEK-Inhibitor ist neben der Checkpointinhibitor-Therapie Standard in der Behandlung des fortgeschrittenen malignen Melanoms mit BRAF-V600-Mutation. In der Phase-III-Studie COLUMBUS erwies sich Encorafenib plus Binimetinib als eine verträgliche Option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Dummer R et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Sabrina Graß

Authors
  1. Sabrina Graß
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Graß, S. Neue BRAF-/MEK-Hemmer-Kombination für Melanomtherapie. Im Focus Onkologie 21, 13–14 (2018). https://doi.org/10.1007/s15015-018-4137-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-4137-1

Search

Navigation